Digest Network Come funziona
Network
/
Società
Ge
Non verificato

GenSight Biologics S.A.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOtticaSalute

15 comunicati stampa

Guarda tutti i comunicati
18/02/2026
Salute
Biotecnologia
Sanità
Medicina - Varie
Ottica
Mercato del lavoro
GenSight Biologics Bolsters Regulatory Leadership in US and Europe with Two Senior Appointments
Fonte
GenSight Biologics S.A.
Emittente
Business Wire
1.00
0
10/02/2026
Biotecnologia
Farmaceutica
Ottica
Sanità
Salute
Medicina - Varie
Mercato del lavoro
Industria
The 15-20 National Hospital and GenSight Biologics Announce the Treatment of the First Patient in the GS010/LUMEVOQ® REVISE Study
Fonte
GenSight Biologics S.A.
Emittente
Business Wire
1.00
0
28/01/2026
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Ottica
GenSight Biologics Announces the Results of its Extraordinary General Meeting of January 28, 2026
Fonte
GenSight Biologics S.A.
Emittente
Business Wire
1.00
0
22/12/2025
Industria
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Ottica
GenSight Biologics Announces Regulatory Authorization for Early Access Treatment with GS010/LUMEVOQ® in Israel
Fonte
GenSight Biologics S.A.
Emittente
Business Wire
1.00
0
22/12/2025
Industria
Salute
Biotecnologia
Farmaceutica
Ottica
GenSight Biologics Announces the Granting of Compassionate Use Authorization (CUA/AAC) for GS010/LUMEVOQ® in France
Fonte
GenSight Biologics S.A.
Emittente
Business Wire
1.00
0
28/08/2025
Biotecnologia
Farmaceutica
Salute
Mercato azionario
Finanza
Web e Social Network
Telefonia e Varie
GenSight Biologics Postpones Release of 2025 Half-Year Financial Results
Fonte
GenSight Biologics S.A.
Emittente
Business Wire
1.00
0
08/04/2025
Biotecnologia
Salute
Farmaceutica
Ottica
GenSight Biologics Announces the Filing of its 2024 Universal Registration Document
Fonte
GenSight Biologics S.A.
Emittente
Business Wire
1.00
0
27/02/2025
Biotecnologia
Salute
Farmaceutica
Ottica
Mercato azionario
GenSight Biologics Reports Estimated Full-Year 2024 Consolidated Financial Results
Fonte
GenSight Biologics S.A.
Emittente
Business Wire
1.00
0
15/01/2025
Industria
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Ottica
GenSight Biologics Announces Publication of 5-Year Outcomes for Patients Treated Unilaterally with LUMEVOQ® Gene Therapy
Fonte
GenSight Biologics S.A.
Emittente
Business Wire
1.00
0
18/12/2024
Biotecnologia
Farmaceutica
Ottica
Salute
GenSight Biologics Provides Update on Regulatory Discussions and Financial Situation
Fonte
GenSight Biologics S.A.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0